Top 5 for the big C
Cegedim Strategic Data tallies cancer treatments in the top 5 European countries
Register for free to listen to this article
Listen with Speechify
0:00
5:00
PARIS—Cegedim Strategic Data (CSD), a leading provider of healthcare market research, has released highlights from its OncoView® study focusing on cancer treatments (excluding hormone therapy) in France, Italy, Germany, Spain and the U.K..
The study uses CSD's OncoView databases for the five countries to collect anonymized patient data through electronic case report forms (e-CRF) from a quarterly panel of 1,400 specialists. The current analysis is based on 110,000 patient cases (raw data) and covers a 12-month projection.
Bladder cancer ranks in the top four treated tumors for all five countries. It ranks second in Italy (15 percent) and Spain (13.2 percent). This is influenced by a wide use of intravesical therapies with chemotherapy by urologists in Italy and a wide use of pre- and post-surgery treatment by urologists for both Italy and Spain. Overall, bladder cancer represents 10 percent of all cancer treatments in the Top 5 European countries.
Notably, the top 10 cancers represent close to 70 percent of all cancer-treated patients (excluding hormone therapy) in the Top 5 European countries.
Between 500,000 and 600,000 patients are treated with target therapies in the Top 5 European countries. In the five countries studied target therapies represent an average of 32 percent of all cancer drugs used. Germany shows the highest rate of target therapy use (36 percent) compared to the other countries. These differences, the report states, are influenced by the launch dates of the drugs and the health authority policies in each country. Cancer types included in the survey were breat, colorectal, non small cell lung cancer, kidney, melanoma, liver, GI stromal tumor, non-Hodgkin lymphoma (aggressive and indolent), multiple myeloma, chronic myeloid leukemia and chronic lymphocytic leukemia.
Founded in 1969, Cegedim is one of the leading suppliers of strategic healthcare industry data. The company employs almost 8,000 people in more than 80 countries and generated revenue of €912 million in 2014. CSD is dedicated to the healthcare industry with more than 40 years' experience in the pharmaceutical industry, Cegedim Strategic Data offers a comprehensive range of market research services and solutions to its customers, which include more than 50 global and 500 local pharmaceutical companies. CSD integrates primary and secondary analyses with its medical expertise to meet its customers’ research needs.
